Here are four Zacks Rank #1 (Strong Buy) stocks that are likely to beat earnings for the week of February 13 th :
Ultra Clean Holdings, Inc. (UCTT): This manufacturer of production tools, modules, and subsystems has witnessed the Zacks Consensus Estimate for its current year earnings surging 5.8% over the last 60 days.
Ultra Clean Holdings, Inc. Price and Consensus
Ultra Clean Holdings, Inc. Price and Consensus | Ultra Clean Holdings, Inc. Quote
The company is expected to report its earnings results for the quarter ending December on Feb 22 and has an Earnings ESP of +7.41%. It has delivered positive earnings surprises in three out of four trailing quarters.
Ultra Clean Holdings, Inc. Price and EPS Surprise
Ultra Clean Holdings, Inc. Price and EPS Surprise | Ultra Clean Holdings, Inc. Quote
Applied Optoelectronics, Inc . (AAOI): This manufacturer and seller of fiber-optic networking products has witnessed the Zacks Consensus Estimate for its current year earnings surging 17.5% over the last 60 days.
Applied Optoelectronics, Inc. Price and Consensus
Applied Optoelectronics, Inc. Price and Consensus | Applied Optoelectronics, Inc. Quote
The company is expected to report its earnings results for the quarter ending December on Feb 23 and has an Earnings ESP of +15.87%. It has delivered positive earnings surprises in three out of four trailing quarters.
Applied Optoelectronics, Inc. Price and EPS Surprise
Applied Optoelectronics, Inc. Price and EPS Surprise | Applied Optoelectronics, Inc. Quote
Milacron Holdings Corp . (MCRN): This manufacturer of engineered and customized systems has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.5% over the last 60 days.
Milacron Holdings Corp. Price and Consensus
Milacron Holdings Corp. Price and Consensus | Milacron Holdings Corp. Quote
The company is expected to report its earnings results for the quarter ending December on Feb 23 and has an Earnings ESP of +11.43%. It has delivered positive earnings surprises in two out of four trailing quarters.
Milacron Holdings Corp. Price and EPS Surprise
Milacron Holdings Corp. Price and EPS Surprise | Milacron Holdings Corp. Quote
Dicerna Pharmaceuticals, Inc. (DRNA): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings advancing 0.3% over the last 60 days.
Dicerna Pharmaceuticals, Inc. Price and Consensus
Dicerna Pharmaceuticals, Inc. Price and Consensus | Dicerna Pharmaceuticals, Inc. Quote
The company is expected to report its earnings results for the quarter ending December on Mar 9 and has an Earnings ESP of +4.11%. It has delivered positive earnings surprises in all four trailing quarters.
Dicerna Pharmaceuticals, Inc. Price and EPS Surprise
Dicerna Pharmaceuticals, Inc. Price and EPS Surprise | Dicerna Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here .
Learn more about Earnings ESP and how you can make it a part of your investing strategy here .
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultra Clean Holdings, Inc. (UCTT): Free Stock Analysis Report
Milacron Holdings Corp. (MCRN): Free Stock Analysis Report
Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report
Applied Optoelectronics, Inc. (AAOI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
